An underground market for unapproved slimming drugs is propelled by social media fitness personalities and vendors on messaging platforms, based on new investigations.
Experimental Treatment Acquiring Traction Via Social Media
Retatrutide, which is still in clinical trials, is being promoted by social media influencers for its alleged fat-burning effects. Viewers are urged to contact these accounts directly for source information, while also obtaining discount codes.
Active Trade on Messaging Platforms
Separately, a robust market exists on messaging services, where groups with numerous of members share “before and after” images, injection guides and assertions of rapid UK delivery. Sellers promote the drug there before directing buyers to other platforms for purchases.
Understanding The Experimental Drug
This medication is an experimental injectable created by American pharmaceutical company Eli Lilly. The drug affects three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could assist individuals lose up to 25% of their body weight. Referred to as the “triple G”, the drug is being hailed digitally as the next Ozempic.
Healthcare Experts Voice Concerns
However, doctors and pharmacists have warned that the distribution of what is still an unlicensed drug in the UK is a cause for concern and could result in individuals administering products of uncertain source.
Some experts said the popularity for the experimental drug could be linked to the increasing price of approved slimming products such as Mounjaro.
Legal Status and Enforcement
Marketing the unapproved drug on social media or messaging apps is illegal in the United Kingdom, as it is an unapproved drug that must not be promoted or distributed for human use under the Human Medicines Regulations 2012.
Several content creators try to circumvent the rules by referring to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled substance, but promotion and supply can still breach medicines, marketing, and consumer regulations, potentially leading to penalties, prosecution or imprisonment.
Platform Response and Content Elimination
According to the social media company, the platform has removed violative material and banned associated keywords and query recommendations. The company stated it was dedicated to keeping the service safe and allocating resources in enhancing compliance measures.
Online Trading Activities
Research also discovered communities with up to 9,000 members selling retatrutide using Telegram's integrated discovery tool, which functions like a online catalog. Typing “retatrutide” instantly brings up groups with thousands of members, filled with photos of slimming results, positive reviews and detailed instructions for mixing or injecting at residence.
After moments of joining one community, a seller posted WhatsApp details, where most transactions occur. The vendor provided an instruction manual and guaranteed delivery within two days. When asked whether the substance was genuine, one vendor said: “You can’t be sure.” Another provided a photo of a alleged testing documentation. None asked about weight, health issues or past usage.
Item Details and Pricing
Inside these groups, messages show black plastic parcels with Royal Mail stickers, stating to include new batches. One message read: “It took eight of us to load them this morning.”
Customers can choose between powder vials, mixed at residence with purified liquid, or pre-filled pens usually sold at £160 for 20mg. When questioned how much time a pen should be used, sellers give conflicting answers ranging from a several days to “depends on your body”.
Platform Oversight and Security Measures
A representative for the messaging service stated it regularly moderated dangerous material on its service including content that promoted the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.
Healthcare Expert Cautions
“Individuals are injecting substances they can’t verify. Although the research behind this drug is valid, these online versions may not include what they claim,” said Jason Murphy, the director of pharmacy at a pharmacy service.
Dr Crystal Wyllie of Asda Online Doctor linked the surge in demand to recent cost increases for authorized weight-loss medications such as Mounjaro. “With costs increasing, patients are turning to social media. But fake treatments are extremely dangerous. You can’t be certain what’s contained or whether the conditions they were produced in was sterile,” she explained.
Her staff has previously encountered patients harmed by personal administration from unverified sources. “We recognize the disappointment, but purchasing from messaging apps or communication platforms is taking chances with your well-being,” stated the doctor. “These substances could be contaminated or incorrectly dosed.”
Manufacturer Statement
A spokesperson from the pharmaceutical company stated the substance was in third stage research studies and had not been evaluated or approved by any regulatory agency anywhere in the world. “Therefore at this point no one can sell [it] for human use,” they explained, noting that any item “falsely representing itself as a Lilly investigational product not yet approved … may subject patients to potentially significant medical dangers”.
